{"doi":"10.1080/02656736.2017.1357210","title":"Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis","abstract":null,"journal":"International Journal of Hyperthermia","year":2017,"id":658593,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":174202,"name":"Sha Liu","orcid":null,"position":1,"is_corresponding":false},{"id":366621,"name":"Xu Liu","orcid":"0000-0003-2252-7148","position":2,"is_corresponding":false},{"id":1719254,"name":"Linxue Qian","orcid":null,"position":3,"is_corresponding":false},{"id":1719257,"name":"Zongli Diao","orcid":null,"position":4,"is_corresponding":false},{"id":1719260,"name":"Wenhu Liu","orcid":null,"position":5,"is_corresponding":false},{"id":255658,"name":"Gang Wang","orcid":"0000-0001-6020-7263","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Microwave ablation: an effective treatment for mild-to-moderate secondary hyperparathyroidism in patients undergoing haemodialysis","abstract":"BACKGROUND: Microwave ablation (MWA) is an effective treatment for severe secondary hyperparathyroidism (SHPT), but it can also be used for mild-to-moderate secondary hyperparathyroidism (SHPT). In this randomised, controlled study, the efficacy of MWA in the treatment of mild-to-moderate hyperparathyroidism is investigated. MATERIALS AND METHODS: We assessed outcomes 12 months after the randomisation of 28 patients with mild-to-moderate SHPT. The subjects received either MWA plus calcitriol or calcitriol alone. The primary end-points were the rate of achieving target levels of intact parathyroid hormone (iPTH), changes in iPTH levels and the rate of patients developing severe SHPT. RESULTS: Primary end points: the overall rates of achieving target levels of iPTH were comparable between the MWA and calcitriol alone groups (24% vs. 22%, p = 0.85). However, the rate of iPTH <150 pg/mL (lower limit of the target range) in the MWA group was higher than that in the calcitriol alone group (23% vs. 8%, p = 0.02). The mean iPTH level in the MWA group after MWA was lower than that in the calcitriol alone group (373.09 ± 322.31 vs. 552.28 ± 361.87 pg/mL, p < 0.001). There was a significant difference in the change in iPTH levels over time within the MWA group (p < 0.001) but not in the calcitriol alone group. Only one patient developed severe SHPT in the MWA group, while six patients in the calcitriol alone group developed severe SHPT (p = 0.04). CONCLUSIONS: Compared with calcitriol alone, MWA plus calcitriol decreases iPTH levels and prevents the progression of mild-to-moderate SHPT.","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28768451","pmcid":null,"openalex_id":"https://openalex.org/W2745153298","authors":[],"funders":[{"funder_name":"Beijing Municipal Administration of Hospitals Incubating Program","grant_id":"013","title":null},{"funder_name":"Beijing Municipal Administration of Hospitals' Youth Program","grant_id":"QML20160101","title":null},{"funder_name":"Beijing Municipal Administration of Hospitals&apos; Youth Program","grant_id":"","title":null}],"total_grants":3,"fwci":1.3665,"citation_percentile":0.80153425,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2018,"count":1},{"year":2019,"count":4},{"year":2020,"count":3},{"year":2021,"count":6},{"year":2022,"count":2},{"year":2023,"count":2},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1357210?needAccess=true&role=button","host_type":"journal"},{"url":"https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1357210?needAccess=true&role=button","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.1080/02656736.2017.1357210","host_type":"publisher"},{"url":"https://doi.org/10.1080/02656736.2017.1357210","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28768451","host_type":"repository"}],"fields_of_study":["Parathyroid Disorders and Treatments","Thyroid and Parathyroid Surgery","Dialysis and Renal Disease Management"],"mesh_terms":["Aged","Calcitriol","Combined Modality Therapy","Female","Humans","Hyperparathyroidism, Secondary","Male","Microwaves","Middle Aged","Parathyroid Glands","Parathyroid Hormone","Vitamins","Treatment Outcome","Ultrasonography, Interventional","Ablation Techniques"],"keywords":["Microwave ablation","Medicine","Secondary hyperparathyroidism","Ablation","Hyperparathyroidism","Surgery","Internal medicine","Parathyroid hormone","Calcium","Calcitriol","Haemodialysis","efficacy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T04:44:12.065311Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}